Categories and Mechanisms of Neurological Injury in IEM

The core dichotomy in neurometabolic disease is small-molecule versus large-molecule IEM. Small-molecule IEMs involve water-soluble intermediary metabolites and include intoxication disorders (organic acidemias, urea cycle disorders, MSUD — toxicity from accumulating metabolites) and energy failure disorders (FAOD, mitochondrial disease, GLUT1 deficiency — fasting-provoked energy deficit). These are often treatable. Large-molecule IEMs are organelle-based storage disorders (lysosomal, peroxisomal, CDG) with progressive structural cellular damage that is usually irreversible. This framework explains why small-molecule IEMs present with episodic acute crises (reversible metabolite accumulation triggered by catabolism) while large-molecule IEMs present with insidious regression (irreversible cellular damage). Importantly, the same gene can produce different phenotypes based on residual enzyme activity — classic PKU vs mild hyperphenylalaninemia, infantile vs late-onset Pompe disease.

Axis	Small-Molecule (Intoxication / Energy)	Large-Molecule (Organelle / Storage)
Biochemical Class	Aminoacidopathies, organic acidemias, UCD, FAOD	LSD, peroxisomal disorders, CDG
Clinical Tempo	Acute / episodic encephalopathy	Insidious regression
Systemic Clues	Hyperammonemia, acidosis, hypoglycemia	Coarse facies, HSM, cherry-red spot
MRI Pattern	Often normal early; BG edema in crisis	Symmetric leukodystrophy / atrophy
Reversibility	Often treatable — DON'T MISS	Generally irreversible
KY NBS	Many captured (PKU, MSUD, PA, MMA, GA1)	Few (Krabbe, Pompe, Fabry)

Key Points

Intoxication IEM: toxic substrate accumulates and causes acute neurological decompensation — aminoacidopathies (MSUD), organic acidemias (MMA, PA, IVA), urea cycle disorders (OTC deficiency) — management is acute detoxification
Energy deficiency IEM: failure to generate sufficient ATP for neural function — mitochondrial respiratory chain disorders, PDH deficiency, fatty acid oxidation defects — may present with Reye-like episodes
Storage disorders (lysosomal, peroxisomal): progressive accumulation of complex molecules in cells — GM1/GM2 gangliosidoses, MPS, Fabry disease, Krabbe, MLD — often slowly progressive
Small molecule deficiencies: deficient production of a critical neuromodulator — BH4 (dopamine, serotonin synthesis), pyridoxine (vitamin B6 — cofactor for GAD and other enzymes), glucose (GLUT1 deficiency)
Metabolic decompensation triggers in IEM: intercurrent illness, fasting, high-protein meal, surgery — catabolism floods the blocked pathway; key concept for acute management

✦ Check Your Understanding

A newborn presents at 5 days of life with poor feeding, alternating hypo- and hypertonia, and a sweet maple syrup odor to the urine. Which amino acid is most specifically elevated and pathognomonic for this condition?

Select an answer to reveal the explanation

Newborn Screening: Principles and Neurometabolic Disorders Detected

Newborn screening (NBS) by tandem mass spectrometry (MS/MS) of dried blood spots has revolutionized early identification of treatable IEM before symptom onset. The US Recommended Uniform Screening Panel (RUSP) includes >35 core conditions and 26 secondary conditions. MS/MS screens for amino acids and acylcarnitines in a single analysis. Expanded NBS programs in some states include dozens more conditions. A positive NBS is a screening result — confirmatory testing is always required before treatment.

Key Points

PKU (PAH deficiency): most common aminoacidopathy detected by NBS; elevated phenylalanine on MS/MS; confirmatory plasma amino acids; treatment with phenylalanine-restricted diet + BH4 (sapropterin) for BH4-responsive variants; pegvaliase (enzyme) for adults
MSUD (maple syrup urine disease): elevated leucine, isoleucine, valine + alloisoleucine (pathognomonic); neonatal encephalopathy with cerebral edema if untreated; branched-chain amino acid restriction; liver transplant corrects enzymatic defect
Urea cycle disorders (OTC deficiency — X-linked, most common): hyperammonemia detected indirectly by elevated citrulline or argininosuccinate; OTC deficiency itself not detected by amino acid NBS — hyperammonemia screen triggered by clinical presentation
Fatty acid oxidation disorders (MCAD, VLCAD, LCHAD): characteristic acylcarnitine profiles; MCAD most common (C8-acylcarnitine); LCHAD causes cardiomyopathy + retinopathy + neuropathy; avoid fasting
False positives are common in premature infants and with poor sample technique — results must always be interpreted with confirmatory biochemical testing before dietary intervention

✦ Check Your Understanding

A neonate presents with severe myoclonic seizures on day 1 of life. Seizures are refractory to phenobarbital and levetiracetam. The most important immediate diagnostic intervention is:

Select an answer to reveal the explanation

Treatable IEM That Must Not Be Missed

Several neurometabolic disorders have specific, highly effective treatments that prevent or reverse neurological damage if started early. Missing these diagnoses has catastrophic consequences. The neurologist's responsibility is to maintain a high index of suspicion, particularly in children with unexplained encephalopathy, seizures, regression, or movement disorder.

Disorder	Mechanism	Key Clue	Don't-Miss Test	Treatment
GLUT1 (SLC2A1)	Glucose transport	Fasting seizures	CSF:serum glucose <0.45	Ketogenic diet
PDE (ALDH7A1)	Antiquitin def.	Refractory neonatal seizures	Urine AASA	Pyridoxine
Biotinidase	Biotin recycling	Seizures / alopecia / rash / SNHL	Enzyme activity	Biotin
Creatine def. (GAMT / AGAT / SLC6A8)	Creatine synth./transport	ID / autism / seizures	Absent MRS creatine; urine Cr:creatinine	Creatine / ornithine
UCD (OTC / CPS1 / ASS1)	Urea cycle	Acute encephalopathy	Ammonia + PAA + urine orotic acid	N-scavengers / dialysis
MSUD	BCKDH def.	Encephalopathy, maple syrup odor	PAA (BCAA)	Leucine restriction
PA / MMA	Organic acidemia	Neonatal acidosis, hyperammonemia, BG stroke	UOA / acylcarnitine C3	Protein restriction
Homocystinuria (CBS)	Methionine metab.	Marfanoid, lens dislocation, DVT	Total homocysteine	Pyridoxine trial
NPC (NPC1/NPC2)	Cholesterol trafficking	VSGP, ataxia, cognitive decline, HSM	Oxysterols	Miglustat
X-ALD (ABCD1)	Peroxisomal β-oxidation	Boys: behavioral / school decline + WM disease	VLCFAs	HSCT
PKU (PAH)	Phe hydroxylase	ID, seizures, tremor	PAA (phenylalanine)	Phe-restricted diet

Key Points

Pyridoxine-dependent epilepsy (ALDH7A1/antiquitin): neonatal/early infantile drug-resistant epilepsy dramatically responsive to pyridoxine (B6) 100 mg IV — always trial B6 in neonatal seizures; urine/plasma pipecolic acid and AASA are biomarkers
Biotinidase deficiency: easily treated with biotin supplementation — if missed, causes sensorineural hearing loss, optic atrophy, ataxia, seizures; detected on NBS but workup required
GLUT1 deficiency syndrome (SLC2A1): the predominant glucose transporter at the blood-brain barrier is deficient; CSF glucose low (CSF:blood glucose ratio <0.45); ketogenic diet provides alternative fuel (ketones freely cross BBB via MCT1); presents with drug-resistant epilepsy, movement disorder, intellectual disability
Homocystinuria (CBS deficiency): elevated homocysteine + methionine; vascular thrombosis risk (stroke), ectopia lentis, Marfan-like habitus, intellectual disability; pyridoxine-responsive in ~50% (B6 cofactor); betaine, methionine restriction
Niemann-Pick disease type C (NPC1/NPC2): vertical supranuclear gaze palsy + ataxia + dementia ± psychosis in adolescent/young adult; cholesterol trafficking defect (impaired NPC1/NPC2-mediated cholesterol export from late endosomes/lysosomes); filipin staining of fibroblasts; miglustat (substrate reduction therapy) slows neurological progression

✦ Check Your Understanding

A 3-year-old child has a CSF glucose of 25 mg/dL with a simultaneous blood glucose of 80 mg/dL (CSF:blood ratio 0.31). She has drug-resistant epilepsy, ataxia, and episodic dystonia. The most appropriate treatment is:

Select an answer to reveal the explanation

Diagnostic Approach to Suspected IEM

Metabolic investigation follows a tiered approach from readily available serum and urine tests to more specialized CSF and enzymatic studies. The clinical presentation guides which metabolic pathways to prioritize. In acute metabolic crises — hyperammonemia, hypoglycemia, lactic acidosis — rapid diagnosis is essential for life-saving treatment.

#	Presentation	Think…	Pearl
1	Acute encephalopathy + hyperammonemia	UCD / OA / FAOD	Treat ammonia, don't wait
2	Lactic acidosis, elevated L:P ratio	Mito / PDH	Single normal lactate doesn't exclude
3	Episodic ataxia / movement crisis	MSUD / OA / mito / UCD / GLUT1	Timing relative to meals is critical
4	Regression after febrile illness	Intoxication IEM / Rett	Partial recovery favors IEM
5	Normal MRI + regression	Early IEM / GLUT1 / creatine / NKH	Normal MRI does NOT exclude IEM
6	Progressive leukodystrophy	MLD / Krabbe / X-ALD / Alexander / VWM	MRI pattern narrows the DDx
7	Cherry-red spot	GM1 / GM2 / NPA / sialidosis	Absence doesn't exclude LSD
8	HSM + neuro decline	NPC / Gaucher 3 / GM1 / MPS	NPC: VSGP classic but subtle
9	Refractory neonatal seizures	PDE / PNPO / NKH / biotinidase / MoCoD	Pyridoxine trial warranted
10	Infant hypotonia + neurodegeneration + hair/CT abnl	Menkes (ATP7A)	Low Cu/Cp; X-linked
11	Adolescent liver + BG signal + psych	Wilson (ATP7B)	KF rings absent in 50%; low Cp
12	ID + movement disorder + absent MRS creatine	Creatine deficiency (SLC6A8)	Urine Cr:creatinine ratio

Stabilize: ABCs, correct hypoglycemia, treat seizures
Acute labs: Ammonia, gas, glucose, lactate, lytes, LFTs, PAA, acylcarnitines, UOA
Categorize: Small vs large molecule, acute vs progressive, multi-organ vs brain-only
Check NBS: Was it done? Normal NBS does NOT exclude all IEMs
First-tier screen: Full panel if not done — collect DURING crisis
Treatable signal? UCD / OA / aminoacidopathy / creatine / PDE / GLUT1 / Wilson / Menkes — immediate consult
Unrevealing? Proceed to WES/WGS without delay — exhaustive sequential testing is outdated

Key Points

Plasma amino acids: quantitative (not qualitative); elevated phenylalanine (PKU), leucine (MSUD), tyrosine (tyrosinemia), glycine (NKH), arginine and citrulline (urea cycle); argininosuccinic acid is pathognomonic of ASA lyase deficiency
Urine organic acids (GC-MS): methylmalonic acid (MMA), propionic acid (PA), 3-methylglutaconic acid (Barth syndrome, DNAJC19), glutaric acid (GA1), lactic acid, ethylmalonic acid (ETHE1); test during acute illness for best yield
Plasma acylcarnitine profile: MCAD (C8↑), VLCAD (C14:1↑), LCHAD/TFP (C16-OH↑), glutaric aciduria type 2 (multiple chain-length acylcarnitines), carnitine transport defect (all acylcarnitines low)
CSF metabolites: essential for neurotransmitter disorders (CSF HVA, 5-HIAA, pterin pattern for DRD), GLUT1 (CSF glucose), folate transport defects (CSF 5-MTHF), NKH (CSF:plasma glycine ratio >0.08 diagnostic)
Enzyme activity assays: required for lysosomal storage disorders (leukocytes or skin fibroblasts); enzyme activity does not always correlate with genotype severity

✦ Check Your Understanding

A 17-year-old boy presents with progressive vertical gaze palsy, cerebellar ataxia, dysarthria, and cognitive decline over 3 years. He had unexplained neonatal jaundice. His sister has a similar presentation. Which diagnostic test is most specific for confirming the suspected diagnosis?

Select an answer to reveal the explanation

Treatment Strategies for Neurometabolic Disorders

Treatment approaches for IEM have expanded dramatically from dietary restriction to include cofactor supplementation, substrate reduction, enzyme replacement therapy (ERT), and increasingly gene therapy. The choice depends on the biochemical mechanism, organ involvement, and availability. Early treatment is critical — neurological damage in most IEM is partially or fully irreversible if accumulated before treatment.

Key Points

Dietary restriction: mainstay for PKU (phenylalanine), MSUD (BCAA), homocystinuria (methionine), GA1 (lysine/tryptophan), galactosemia (galactose); requires specialized formulas; adherence challenging lifelong
Cofactor supplementation: pyridoxine (PDE, B6-responsive homocystinuria, B6-responsive seizures), biotin (biotinidase deficiency, MCD), BH4/sapropterin (BH4-responsive PKU, DRD), riboflavin (MADD, complex I/II), thiamine (thiamine-responsive disorders)
Enzyme replacement therapy (ERT): Fabry (agalsidase beta — Fabrazyme); Pompe/GSD type II (alglucosidase alfa — Myozyme/Lumizyme); MPS I (laronidase), MPS II (idursulfase), Gaucher (imiglucerase) — IV infusions; CNS penetration limited by BBB
Substrate reduction therapy: miglustat and eliglustat (Gaucher, NPC) — oral small molecules inhibiting substrate synthesis; useful when ERT has limited CNS access
Gene therapy advances: OTC deficiency (Phase 1/2 AAV8 liver-directed trials), GA1, MMA (mRNA therapy); SMA approved 2019 (onasemnogene abeparvovec, Zolgensma) — paradigm for IEM gene therapy; ex vivo gene therapy for MLD (atidarsagene autotemcel, Libmeldy) approved in EU

✦ Check Your Understanding

Enzyme replacement therapy (ERT) is available for several lysosomal storage disorders but has limited efficacy for CNS manifestations. The primary reason is:

Select an answer to reveal the explanation

0 of 5 sections read

Scroll through all sections to track your progress.